Identification of oxidative degradation impurities of Olanzapine drug substance as well as drug product

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 2, 2011, Pages 413-418

  Rao, P Sreenivasa ^a   Ray, Uttam Kumar ^a   Hiriyanna, S G ^a   Rao, Sumathi V ^a   Sharma, Hemant Kumar ^a   Handa, Vijay Kumar ^a   Mukkanti, K ^b  

^a Aurobindo Pharma Ltd   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Impurities; Isolation; Olanzapine; Oxidative degradation; Structure elucidation

Indexed keywords

4 (4 METHYL 1 PIPERAZINYL) 3 ACETOXYMETHYLIDENE 1H BENZO[B][1,4]DIAZAPINE 2(3H)THIONE(ACETOXYMETHYLIDENE THIONE); 4 (4 METHYL 1 PIPERAZINYL) 3 HYDROXYMETHYLIDENE 1H BENZO[B][1,4]DIAZEPINE 2(3H)THIONE(HYDROXYMETHYLIDENETHIONE); DRUG METABOLITE; OLANZAPINE; UNCLASSIFIED DRUG;

ARTICLE; DEGRADATION KINETICS; DRUG FORMULATION; DRUG IMPURITY; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION; OXIDATION KINETICS; PRIORITY JOURNAL;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; DRUG STABILITY; EXCIPIENTS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; TABLETS; TANDEM MASS SPECTROMETRY; TECHNOLOGY, PHARMACEUTICAL;

EID: 79960056570     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.05.003     Document Type: Article

References (14)

1. Chakrabarti J.K., Horsman L., Hotten T.M., Pullar I.A., Tupper D.E., Wright F.C. 4-piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as potential neuroleptics. J. Med. Chem. 1980, 23:878-884.
2. Chakrabarti J.K., Fairhust J., Gutteride N.J.A., Horsman L., Pullar I.A., Smith C.W., Tupper D.E., Wright F.C. 10-piperazinyl-4H-thieno[2,3-b][1,5]benzodiazepines as potential neuroleptics. J. Med. Chem. 1980, 23:884-889.
3. Calligaro D.O., Fairhust J., Hotten T.M., Moore N.A., Tupper D.E. The synthesis and biological activity of some known and putative metabolites of the atypical antipsychotic agent Olanzapine (LY170053). Bioorg. Med. Chem. Lett. 1997, 7:25-30.
4. J.K. Chakrabarti, D.E. Tupper, Thieno[1,5]benzodiazepines, Ger. Offen 2,552,403 (CA 86: 29893e).
5. C.J. Kumar, H.T. Michael, T.D. Edward, Preparation of 2-methyl-4-(4-methyl-1-piperzinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, Eur. Pat. Appl. EP 454,436 (CA 116: 83703u).
6. B.C.H. Barry Arnold, L. Samuel Dear, Olanzapine polymorph crystal form pharmaceutical. U.S. US 5,736,541 (CA 128: 261935d).
7. Pollla G.I., Vega D.R., Lanza H., Tombari D.G., Baggia R., Ayala A.P., Filho J.M., Fernandez D., Leyva G., Dartayet G. Thermal behaviour and stability in Olanzapine. Int. J. Pharm. 2005, 301:33-40.
8. Baetrschi S.W., Brunner H., Bunnell C.A., Cooke G.G., Diseroad B., Dorman D.E., Jansen P.J., Kemp C.A.J., Maple S.R., McCune K.A., Speakman J. Isolation, identification, and synthesis of two oxidative degradation products of Olanzapine (LY170053) in solid oral formulations. J. Pharm. Sci. 2008, 97:883-892.
9. Hiriyanna S.G., Basavaiah K., Goud P.S.K., Dhayanithi V., Raju K., Pati H.N. Identification and characterization of Olanzapine degradation products under oxidation stress condition. Acta Chromatogr. 2008, 20:81-93.
10. Rao R.N., Raju A.N., Narasimha R., Babu G.R. Isolation, and characterization of process related impurities of Olanzapine using HPLC and ESI-MS/MS. J. Sep. Sci. 2008, 31:107-118.
11. USP Monographs, Olanzapine and Olanzapine Tablets, vol. 33.
12. Pharmeuropa, vol. 20, October 2008.
13. Guidance for Industry: Q3B (R2) Impurities in New Drug Products, International Conference On Harmonization, 2006.
14. Yohoyama T., Nohara F. The peracid oxidation of ketones. III. The reaction of α, β-unsaturated ketones with peroxybenzoic acid. Bull. Chem. Soc. Jpn. 1965, 38:1498-1500.